Axxcess Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Axxcess Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-488	Closed	-$377K	–	858
2025 Q4	$377K	Buy	488 +4	+0.8%	+$2.72K	0.01%	779
2025 Q3	$272K	Buy	484 +45	+10%	+$25.4K	0.01%	788
2025 Q2	$230K	Buy	+439	New	+$245K	0.01%	796
2022 Q4	–	Sell	-563	Closed	-$388K	–	669
2022 Q3	$388K	Buy	563 +10	+2%	+$6.29K	0.04%	359
2022 Q2	$327K	Sell	553 -20	-3%	-$13K	0.03%	376
2022 Q1	$400K	Buy	573 +101	+21%	+$63.9K	0.03%	409
2021 Q4	$298K	Buy	+472	New	+$290K	0.02%	472

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Axxcess Wealth Management's REGN Position: Q1 2026 in Review

Axxcess Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 488 shares — an estimated $377K sold.

Axxcess Wealth Management first reported a position in REGN in Q4 2021 and held it in 7 quarters. The position peaked at $400K in Q1 2022. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Axxcess Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Axxcess Wealth Management sold 488 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $377K.
Axxcess Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 7 quarters.
Axxcess Wealth Management's Regeneron Pharmaceuticals position peaked at $400K in Q1 2022.
1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Axxcess Wealth Management's 13F filing for Q1 2026, filed 29 Apr 2026.